EUVIMEDEUVIMED entdecken
Crossref

New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant

Georgios Schoretsanitis, Erich Seifritz, Michael Paulzen

Psychopharmakotherapie · 2025 · 32 (7) · 1112-1116

DOI: 10.52778/ppt20250037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmakotherapie, 2025. Verfasst von Georgios Schoretsanitis und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Schoretsanitis, G., Seifritz, E., & Paulzen, M. (2025). New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant. Psychopharmakotherapie, 32(7), 1112-1116. https://doi.org/10.52778/ppt20250037

Vancouver

Schoretsanitis G, Seifritz E, Paulzen M. New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant. Psychopharmakotherapie. 2025;32(7):1112-1116. doi:10.52778/ppt20250037

BibTeX
@article{Schoretsanitis2025,
  author = {Schoretsanitis, Georgios and Seifritz, Erich and Paulzen, Michael},
  title = {New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant},
  journal = {Psychopharmakotherapie},
  year = {2025},
  volume = {32},
  number = {7},
  pages = {1112--1116},
  doi = {10.52778/ppt20250037}
}
Kostenlos starten →